RSSPsoriasis

An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis

An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis

| May 1, 2018

by Jerry Bagel, MD, MS, and Elise Nelson, LPN, CCRC Both authors are with the Psoriasis Treatment Center of Central New Jersey in East Windsor, New Jersey. J Clin Aesthet Dermatol. 2018;11(5):27–29 Funding: This study was sponsored by Taro Pharmaceuticals U.S.A., Inc. Disclosures: The authors have no conflicts of interest relevant to the content of […]

Continue Reading

Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis

Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis

| May 1, 2018

by Saakshi Khattri, MD; Orin Goldblum, MD; Kathleen Solotkin, MSN; Yasmin Amir, MD; Michelle S. Min, MD, MSci; Terri Ridenour, BSN, MBA; Fan Emily Yang, PhD; and Mark Lebwohl, MD, FAAD Dr. Khattri, Dr. Amir, Dr. Min, and Dr. Lebwohl are with the Department of Dermatology at the Icahn School of Medicine at Mount Sinai […]

Continue Reading

Efficacy, Safety, and Potency of Betamethasone Dipropionate Spray 0.05%: A Treatment for Adults with Mild-to-moderate Plaque Psoriasis

Efficacy, Safety, and Potency of Betamethasone Dipropionate Spray 0.05%: A Treatment for Adults with Mild-to-moderate Plaque Psoriasis

| April 1, 2018

by Srinivas Sidgiddi, MD, Refika I. Pakunlu, PhD, and Kent Allenby, MD Drs. Sidgiddi, Pakunlu, and Allenby are with Promius Pharma, a subsidiary of Dr. Reddy’s Laboratories, in Princeton, New Jersey. Funding: This study was funded and sponsored by the Dr. Reddy’s Laboratories group of companies in Princeton, New Jersy, USA Disclosures: Drs. Sidgiddi, Pakunlu, […]

Continue Reading

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting

| September 1, 2017

by Jo Ann LeQuang Ms. LeQuang is a medical writer with LeQ Medical in Angleton, Texas. This article is based on selected proceedings of the 2017 MauiDerm meeting, which was held March 20–24, 2017, at the Grand Wailea in Maui, Hawaii. Presentations included those by Brian Berman, MD; Roger I. Ceilley, MD; Linda Stein Gold, […]

Continue Reading

Oral Apremilast for the Treatment  of Plaque Psoriasis

Oral Apremilast for the Treatment of Plaque Psoriasis

| September 1, 2016

James Q. Del Rosso, DO; Leon Kircik, MD Disclosures (related to this manuscript): Dr. Del Rosso is a speaker, consultant, and/or researcher for Anacor, Aqua, Allergan, Bayer, Celgene, Galderma, LeoPharma, Novartis, Pharmaderm, Promius, SunPharma, and Valeant. Dr. Kircik is either a speaker, consultant, or investigator for Amgen, Anacor, Aqua, Allergan, Bayer, Celgene, Coherus, Eli Lilly, […]

Continue Reading

Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas

Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas

| September 14, 2010 | 0 Comments

Joshua A. Zeichner, MD Mount Sinai Medical Center, New York, New York Disclosure: Dr. Zeichner is a consultant for Promius Pharma. Abstract Psoriasis in some body parts can be challenging to treat. Psoriasis in the scalp, palms and soles, and intertriginous areas differ from disease on other body parts, and treatment regimens must be tailored […]

Continue Reading

A Practical Approach to Monitoring Patients on Biological Agents for the Treatment of Psoriasis

A Practical Approach to Monitoring Patients on Biological Agents for the Treatment of Psoriasis

| August 5, 2010 | 0 Comments

Jason J. Emer, MD; Amylynne Frankel, MD; Joshua A. Zeichner, MD Mount Sinai School of Medicine, Department of Dermatology, New York, New York Disclosure: Drs. Emer and Frankel report no relevant conflicts of interest. Dr. Zeichner is an investigator for Centocor. Abstract Psoriasis is a chronic, systemic, inflammatory skin condition that manifests predominantly as well-demarcated, […]

Continue Reading